<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/F8C430BA-13B7-459A-8D47-AC5064090714"><gtr:id>F8C430BA-13B7-459A-8D47-AC5064090714</gtr:id><gtr:name>Os (Realisations) Limited</gtr:name><gtr:address><gtr:line1>COBALT CONCORDE HOUSE , TRINITY PARK</gtr:line1><gtr:city>SOLIHULL</gtr:city><gtr:postCode>B37 7UQ</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F8C430BA-13B7-459A-8D47-AC5064090714" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>F8C430BA-13B7-459A-8D47-AC5064090714</gtr:id><gtr:name>Os (Realisations) Limited</gtr:name><gtr:address><gtr:line1>COBALT CONCORDE HOUSE , TRINITY PARK</gtr:line1><gtr:city>SOLIHULL</gtr:city><gtr:postCode>B37 7UQ</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>21500.0</gtr:offerGrant><gtr:projectCost>35833.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/2302EC1F-F937-4333-8DBA-121D21DB3882"><gtr:id>2302EC1F-F937-4333-8DBA-121D21DB3882</gtr:id><gtr:firstName>Ben</gtr:firstName><gtr:surname>Capewell</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=700133"><gtr:id>F099F841-7A6A-465D-9166-F009D7666E55</gtr:id><gtr:title>Low Energy Cold Plasma Ionisation Air Cleansing Project (LECPI)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Market</gtr:grantCategory><gtr:grantReference>700133</gtr:grantReference><gtr:abstractText>OSIL proposes to introduce LECPI technology to change the chemistry of air in enclosed
environments to remove bacteria and other contaminants at source. This is to be achieved by
introducing purpose designed units. LECPI enhances air quality by activating oxygen to use
its natural qualities to remove bacteria and pollutants.
The purpose of a comprehensive marketing report is to verify target markets and analyse their
characteristics, volumes and suitability for LECPI technology. Benefits of LECPI in removing
bacteria is suited to healthcare and hygiene controlled environments. OSIL has identified this
key future market as an opportunity for domestic and export penetration.
LECPI produces streams of purifying oxygen ions. These are a harmless natural cleansing
agent proven to kill bacteria and remove pollutants. This is achieved by generating low-speed
electrons and allowing them to activate oxygen within their environment. This method
prevents formation of dangerous ozone and other harmful compounds as produced by other
plasma systems. This allows a greater formation of negatively charged oxygen ions to create
oxidation reactions. This breaks down odorous chemical components and bacteria cell walls.
Negative charge causes oxygen ions to cluster and hydrolyse cell walls allowing particles to
become electro-statically charged and become too dense to remain in free circulation.
Current uses of plasma ionisation require multiple operational processes to function safely.
LECPI has the ability to cleanse the air in a single controlled process. Traditional plasma
ionisation technology produces harmful ozone and positively charged ions. The proposal sets
out to solve and remove ozone hazards.
The project objectives are to research and produce a full marketing and strategic report on
hospitals and healthcare institutions and the route to introduction of LECPI technology.
There is a lead to other industrial uses if the premium hospital markets could be activated.</gtr:abstractText><gtr:fund><gtr:end>2012-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2012-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>21500</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">700133</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>